How would you approach a young patient with a prior ER+ HER2- breast CA now local recurrence that now has Her2 positive disease?
If a patient previously received taxane-based chemotherapy for the initial cancer, is additional chemotherapy recommended or can HER2-directed and hormonal therapy be sufficient? Would you use combination therapy with trastuzumab + pertuzumab or trastuzumab alone?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Huntsman Cancer Institute at the University of Utah
Answered on · Updated on
For Her-2 positive disease, I would definitely choose chemotherapy with anti Her-2 agent(s). With Her-2 positivity and a young age, the patient is at high risk for recurrence which can be significantly reduced by the addition of anti Her-2 agents to chemotherapy. Although this is a local recurrence,...
Join for free or sign in to see the full answer